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Summary
The ARISTOTLE trial showed a risk reduction of stroke/systemic embol-
ism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) 
patients treated with apixaban compared to warfarin. This retrospec-
tive study used four large US claims databases (MarketScan, PharMet-
rics, Optum, and Humana) of NVAF patients newly initiating apixaban 
or warfarin from January 1, 2013 to September 30, 2015. After 1:1 
warfarin-apixaban propensity score matching (PSM) within each data-
base, the resulting patient records were pooled. Kaplan-Meier curves 
and Cox proportional hazards models were used to estimate the 
cumulative incidence and hazard ratios (HRs) of stroke/SE and major 
bleeding (identified using the first listed diagnosis of inpatient claims) 
within one year of therapy initiation. The study included a total of 
76,940 (38,470 warfarin and 38,470 apixaban) patients. Among the 
38,470 matched pairs, 14,563 were from MarketScan, 7,683 were 
from PharMetrics, 7,894 were from Optum, and 8,330 were from Hu-
mana. Baseline characteristics were balanced between the two co-
horts with a mean (standard deviation [SD]) age of 71 (12) years and a 
mean (SD) CHA2DS2-VASc score of 3.2 (1.7). Apixaban initiators had a 
significantly lower risk of stroke/SE (HR: 0.67, 95 % CI: 0.59–0.76) and 
major bleeding (HR: 0.60, 95 % CI: 0.54–0.65) than warfarin initiators. 
Different types of stroke/SE and major bleeding – including ischaemic 
stroke, haemorrhagic stroke, SE, intracranial haemorrhage, gastroin-
testinal bleeding, and other major bleeding – were all significantly 
lower for apixaban compared to warfarin treatment. Subgroup ana-
lyses (apixaban dosage, age strata, CHA2DS2-VASc or HAS-BLED score 
strata, or dataset source) all show consistently lower risks of stroke/SE 
and major bleeding associated with apixaban as compared to warfa-
rin treatment. This is the largest “real-world” study on apixaban effec-
tiveness and safety to date, showing that apixaban initiation was as-
sociated with significant risk reductions in stroke/SE and major bleed-
ing compared to warfarin initiation after PSM. These benefits were 
consistent across various high-risk subgroups and both the standard- 
and low-dose apixaban dose regimens.
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Introduction
Atrial fibrillation (AF) is recognised as the most common sustained 
cardiac arrhythmia in the United States and is associated with a 
nearly five-fold excess of stroke (1). AF prevalence in the United 
States was estimated at 5.2 million in 2010 and is projected to be-
come 12.1 million in 2030, with an annual increase of 4.3 % (2).
Vitamin K antagonists (VKAs; e.g. warfarin) have been the 
mainstay treatment in stroke prevention for AF patients for several 
decades, reducing stroke among AF patients by 64 % compared to 
a control or placebo; however, an increased risk of major bleeding 
was observed when compared with no anticoagulant treatment or 
placebo (3, 4). In addition to a higher risk of major bleeding, war-
farin treatment is hindered by its narrow therapeutic range, drug 
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and food interactions, the requirement of regular blood test moni-
toring of the international normalised ratio (INR), and frequent 
need of dose adjustment (5).
The non-VKA oral anticoagulants (NOACs) – including dabi-
gatran, rivaroxaban, apixaban, and edoxaban – were approved for 
stroke prevention in non-valvular atrial fibrillation (NVAF) pa-
tients by the US Food and Drug Administration in October 2010, 
November 2011, December 2012, and January 2015, respectively. 
Compared to warfarin, no anticoagulation monitoring is required 
and fewer drug and food interactions are evident (6). In Phase 3 
clinical trials, all four NOACs are at least as efficacious and safe as 
warfarin (7–10). Apixaban is the only NOAC to show risk reduc-
tion in both stroke/systemic embolism (SE) and major bleeding 
compared to warfarin in its Phase 3 trial (ARISTOTLE) (9). Apixa-
ban is used to treat NVAF in two dosing forms: 5 mg and 2.5 mg. 
Apixaban 5 mg is recommended to most patients, and the reduced 
apixaban 2.5 mg is only recommended to patients who meet at 
least two of three criteria: age ≥80 years, body weight ≤60kg, and 
serum creatinine ≥1.5 mg/dl (11).
“Real-world” observational studies have been conducted to es-
timate the effectiveness and safety of oral anticoagulants (OACs; 
including VKAs and NOACs) outside clinical trial settings. Since 
apixaban was approved only in December 2012, few studies have 
evaluated apixaban; prior “real-world” studies were limited by 
sample size and follow-up duration, particularly for effectiveness 
endpoints.
An a priori power calculation was completed based on the 
event rates observed in the ARISTOTLE trial and an estimated du-
ration of follow-up in US claims datasets: an estimated 25,000 pa-
tients are needed to adequately examine the effectiveness of apixa-
ban compared to warfarin (with an alpha of 0.05 and power of 
80 %). Thus, to achieve the required sample size, this retrospective 
study was conducted using pooled data from four US claims data-
sets. The risk of primary endpoints in the ARISTOTLE trial 
(stroke/SE and major bleeding) was compared among treatment-
naïve NVAF patients who were prescribed warfarin or apixaban.
Materials and methods
Data sources
Data in this study were pooled from four large, nationally-repre-
sentative claims databases in the US – Truven MarketScan® Com-
mercial Claims and Encounter and Medicare Supplemental and 
Coordination of Benefits Database (“MarketScan”) (12), IMS 
PharMetrics Plus™ Database (“PharMetrics”) (13), Optum Clin-
formatics™ Data Mart (“Optum”) (14), and Humana Research Da-
tabase (“Humana”) (15) – from January 1, 2012 to September 30, 
2015. The four datasets include claims from over 163 million 
members of commercial and Medicare Advantage/supplemental 
plans. The datasets contain information on patient demographics 
and enrolment history as well as medical claims from inpatient 
hospital, outpatient hospital, emergency room, physician’s office, 
and surgery centres. The medical claims are coded using Inter-
national Classification of Disease, 9th Revision, Clinical Modifica-
tion (ICD-9-CM), Current Procedural Terminology, or Healthcare 
Common Procedure Coding System codes. Pharmacy claims in-
clude the drug dispensed using the National Drug Code coding 
system. Although lacking clinical richness, these claims datasets 
provide access to the healthcare experience of millions of patients 
across continuum of care setting over a multiyear period of time, 
and have often been used in pharmacoepidemiology and pharma-
covigilance studies, comparative effectiveness research, and health 
care economic analyses. These datasets have also been used in pre-
vious pooled analyses of various therapeutic areas (16–19), includ-
ing one analysis using the MarketScan and Optum datasets on the 
comparative effectiveness and safety of dabigatran versus warfarin 
in NVAF patients (20). The Optum and Humana databases con-
tain information of beneficiaries from unique insurance plans, 
which guarantees no duplicates on the health-plan level when 
pooled with other datasets. The other two datasets contain infor-
mation from employer-provided health plans, with reported po-
tential duplicates of only 0.5 % in a study using both datasets (21).
Patient selection
NVAF patients who were aged ≥18 years and had ≥1 pharmacy 
claim for apixaban or warfarin during the identification period 
(January 1, 2013 to September 30, 2015) were included in the 
study. AF patients were identified using ICD-9-CM code 427.31, a 
validated code used to identify AF patients with a median positive 
predictive value of 89 % (22). The date of the first apixaban or war-
farin pharmacy claim during the identification period was desig-
nated as the index date. Patients were required to have the AF di-
agnosis before or on the index date and have continuous medical 
and pharmacy health plan enrolment for ≥12 months prior to the 
index date.
Patients with evidence of valvular heart disease, venous throm-
boembolism, transient AF (pericarditis, hyperthyroidism, thyrot-
oxicity), or heart valve replacement/transplant during the 12 
months prior to or on the index date, or with pregnancy during 
the study period were excluded. Patients treated with any OACs 
within 12 months before the index date or with >1 OAC on the 
index date were also excluded.
Outcome measures
The outcome measures were stroke/SE and major bleeding events 
identified using the first listed ICD-9-CM diagnosis of inpatient 
claims. The diagnosis codes used for stroke/SE and major bleeding 
were based on a validated administrative claim-based algorithm as 
well as the International Society on Thrombosis and Haemostasis’ 
definition of major bleeding as used in the ARISTOTLE trial 
(Suppl. Table 1, available online at www.thrombosis-online.com) 
(9, 23, 24). Stroke/SE was further stratified by ischaemic stroke, 
haemorrhagic stroke, and SE; major bleeding was further stratified 
by gastrointestinal (GI) bleeding, intracranial haemorrhage (ICH), 
and other major bleeding. To assess the outcomes, patients were 
followed from the day after the index date and were censored at 
the first outcome event, 30 days after the discontinuation date, the 
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Table 1: Baseline characteristics for propensity score matched apixaban and warfarin patients.
Age (years)
 18–54
 55–64
 65–74
 ≥75
Gender
 Male
 Female
US Geographic Region
 Northeast
 Midwest
 South
 West
 Other
Baseline Comorbidity
Deyo-Charlson Comorbidity 
Index Score
CHADS2 Score
 0
 1
 2
 3+
CHA2DS2-VASc Score
 0
 1
 2
 3
 4+
HAS-BLED Scorea
 0
 1
 2
 3+
Bleeding history
Congestive heart failure
Diabetes mellitus
Warfarin Cohort
(N=38,470)
N/Mean
70.9
3,304
8,942
10,660
15,564
23,015
15,455
5,911
10,264
16,186
5,817
292
2.5
2.1
3,444
10,151
12,542
12,333
3.2
2,326
3,959
6,896
8,748
16,541
2.6
1,918
6,101
11,198
19,253
6,303
9,210
12,629
%/SD
11.9
8.6 %
23.2 %
27.7 %
40.5 %
59.8 %
40.2 %
15.4 %
26.7 %
42.1 %
15.1 %
0.8 %
2.5
1.3
9.0 %
26.4 %
32.6 %
32.1 %
1.7
6.1 %
10.3 %
17.9 %
22.7 %
43.0 %
1.3
5.0 %
15.9 %
29.1 %
50.0 %
16.4 %
23.9 %
32.8 %
Apixaban Cohort 
(N=38,470)
N/Mean
70.9
3,203
8,962
10,665
15,640
22,946
15,524
5,949
10,337
16,146
5,739
299
2.5
2.1
3,637
10,266
12,002
12,565
3.2
2,477
4,008
6,911
8,388
16,686
2.6
1,939
6,158
10,950
19,423
6,393
9,320
12,501
%/SD
12.0
8.3 %
23.3 %
27.7 %
40.7 %
59.7 %
40.4 %
15.5 %
26.9 %
42.0 %
14.9 %
0.8 %
2.4
1.3
9.5 %
26.7 %
31.2 %
32.7 %
1.8
6.4 %
10.4 %
18.0 %
21.8 %
43.4 %
1.4
5.0 %
16.0 %
28.5 %
50.5 %
16.6 %
24.2 %
32.5 %
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Hypertension
Renal disease
Liver disease
Myocardial infarction
Dyspepsia or stomach 
 discomfort
Non-stroke/SE peripheral 
 vascular disease
Stroke/SE
Transient ischaemic attack
Anaemia and coagulation 
 defects
Alcoholism
Baseline Medication Use
 ACE/ARB
 Amiodarone
 Beta blockers
 H2-receptor antagonist
 Proton pump inhibitor
 Statins
 Anti-platelets
 NSAIDs
Apixaban Dose on Index Date
 Standard (5 mg)
 Reduced (2.5 mg)
Follow-up Time (in days)
 Median
Follow-up Time (in days) 
 Restricted to 1 Year
 Median
SD: standard deviation; SE: systemic embolism; CHADS2: congestive heart fail-
ure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient 
ischaemic attack or thromboembolism; CHA2DS2-VASC: congestive heart 
failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or tran-
sient ischaemic attack or thromboembolism, vascular disease, age 65–74 
years, sex category; HAS-BLED: hypertension, abnormal renal and liver func-
tion, stroke, bleeding, labile INRs (international normalised ratio), elderly, 
drugs and alcohol; ACE: angiotensin-converting enzyme inhibitor; ARB: an-
giotensin-receptor blocker; NSAIDs: non-steroidal anti-inflammatory drugs. 
aas the INR value is not available in the databases, a modified HAS-BLED score 
was calculated with a range of 0 to 8.
Warfarin Cohort
(N=38,470)
N/Mean
31,672
7,660
1,653
3,372
6,514
17,269
3,812
2,360
7,221
797
22,727
4,174
23,005
1,984
10,479
21,891
5,995
8,953
-
-
199.9
122.0
165.7
122.0
%/SD
82.3 %
19.9 %
4.3 %
8.8 %
16.9 %
44.9 %
9.9 %
6.1 %
18.8 %
2.1 %
59.1 %
10.9 %
59.8 %
5.2 %
27.2 %
56.9 %
15.6 %
23.3 %
-
-
193.8
-
117.3
-
Apixaban Cohort 
(N=38,470)
N/Mean
31,752
7,628
1,705
3,424
6,633
17,337
3,922
2,389
7,141
809
22,562
4,221
23,111
1,992
10,636
21,754
6,093
9,045
31,926
6,568
179.2
119.0
158.2
119.0
%/SD
82.5 %
19.8 %
4.4 %
8.9 %
17.2 %
45.1 %
10.2 %
6.2 %
18.6 %
2.1 %
58.6 %
11.0 %
60.1 %
5.2 %
27.6 %
56.5 %
15.8 %
23.5 %
83.0 %
17.1 %
163.2
-
114.8
-
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receipt date of a prescription for an OAC other than the index 
therapy, inpatient death, end of continuous medical and pharmacy 
enrolment, one year post-index date, or the end of study period 
(September 30, 2015), whichever occurred first. Discontinuation 
was defined as no evidence of index warfarin or apixaban pre-
scription for 30 days from the last day of supply of the last filled 
prescription (25). Patients were censored one year post-index date 
in order to balance the follow-up period between the apixaban and 
warfarin cohorts.
Statistical methods
Propensity score matching (PSM) was conducted between the 
warfarin and apixaban cohorts. Nearest neighbour without re-
placement with a calliper of 0.01 was used to match the patients 
(26). Patients were matched 1:1 within each dataset on the propen-
sity scores generated by logistic regressions based on age, gender, 
geographic region, Charlson Comorbidity Index (CCI) score, 
baseline bleeding and stroke/SE history, comorbidities, and base-
line co-medications. The balance of covariates was checked based 
on standardised differences with a threshold of 10 % (27). The four 
datasets were pooled after ensuring the cohorts were balanced.
Cox proportional hazard models with robust sandwich esti-
mates were performed to evaluate the risk of stroke/SE and major 
bleeding between the two matched cohorts (26). Apixaban or war-
farin treatment was included as the independent variable, and no 
other covariates were included in the model because the cohorts 
were balanced. The proportional hazards assumption was checked 
by visual inspection of log-log of the Kaplan-Meier survival 
curves.
Subgroup analyses
Subgroup analyses were completed based on initial apixaban dose, 
age strata, CHA2DS2-VASc score, HAS-BLED score, and the data-
set source. For the dose subgroup analysis, apixaban standard dose 
(5 mg) and reduced dose (2.5 mg) subgroups were created based 
on the index apixaban prescription dosage. Each warfarin patient 
was assigned to one of the two subgroups according to the dose of 
the apixaban patient she/he matched with. For the age subgroup 
analysis, patients in the pooled dataset were categorised into three 
subgroups: <65, 65–74, and ≥75 years. For the CHA2DS2-VASc 
score subgroup analysis, patients were categorised by scores of <2, 
2–3, and ≥4; for the HAS-BLED subgroup analysis, patients were 
categorised by scores of <3 and ≥3 (as the INR value is not avail-
able in the databases, a modified HAS-BLED score was calculated 
with a range of 0 to 8). In each subgroup, the balance of baseline 
characteristics between apixaban and warfarin patients was evalu-
ated. When the standardized difference was >10 %, the covariate 
was included in the Cox proportional hazards model. In each sub-
group analysis, the statistical significance (p-value < 0.10) of the 
interaction between treatment and the specific subgroup(s) was 
evaluated.
Sensitivity analysis
A sensitivity analysis was conducted without restricting the follow-
up period to one year. In this analysis, patients were not censored 
one year post-index date.
Results
Baseline characteristics
After applying the selection criteria, a total of 115,186 NVAF pa-
tients newly initiated on warfarin or apixaban were identified, in-
cluding 41,867 apixaban and 73,319 warfarin patients. Before 
PSM, warfarin patients were significantly older and had higher 
CCI, CHA2DS2-VASc, and HAS-BLED scores compared to apixa-
ban patients in each of the four datasets. After PSM, a total of 
76,940 (38,470 warfarin and 38,470 apixaban) patients were in-
cluded in the final analysis (14,563 pairs from MarketScan, 7,683 
pairs from PharMetrics, 7,894 pairs from Optum, and 8,330 pairs 
from Humana), and the two matched cohorts were well balanced 
(▶ Figure 1).
The mean age for the matched warfarin and apixaban cohorts 
was 71 years. The mean CCI, CHA2DS2-VASc, and HAS-BLED 
scores were 2.5, 3.2, and 2.6, respectively. Approximately 16 % of 
the patient population had a prior bleed, and about 10 % had 
stroke/SE during the baseline period. 17 % of patients were pre-
scribed reduced-dose apixaban on the index date. Compared with 
patients enrolled in the ARISTOTLE trial, patients in this “real-
world” study were more likely to be aged ≥75 years and female, 
had similar mean CHADS2 scores, and had similar percentage of 
patients with bleeding history (Suppl. Table 2, available online at 
www.thrombosis-online.com) (9). For the main analysis, we re-
stricted the follow-up to one year, which created a more similar 
follow-up length between the two cohorts (mean: 166 vs 158 days; 
median: 122 vs 119 days) (▶ Table 1).
Stroke/SE
The incidence of stroke/SE was 2.3 and 3.5 per 100 person-years 
(PY) for apixaban and warfarin patients, respectively (▶ Table 2). 
The cumulative incidence of stroke/SE and major bleeding is 
shown in ▶ Figure 2. Compared to warfarin, apixaban was associ-
ated with a 33 % lower risk of stroke/SE (hazard ratio [HR]: 0.67, 
95 % confidence interval [CI]: 0.59–0.76, p<0.001) within one year 
of treatment initiation and driven by a reduction in the risk of 
haemorrhagic stroke (HR: 0.70, 95 % CI: 0.50–0.99, p=0.041), is-
chaemic stroke (HR 0.67, 95 % CI 0.58–0.76, p<0.001), and SE 
(HR: 0.46, 95 % CI: 0.26–0.82, p=0.008) (▶ Figure 3).
Major bleeding
The incidence of major bleeding for apixaban and warfarin pa-
tients was 4.5 and 7.5 per 100 PY, respectively (▶ Table 2). Com-
pared to warfarin, apixaban use was associated with a 40 % lower 
risk of major bleeding (HR: 0.60, 95 % CI: 0.54–0.65, p<0.001) 
© Schattauer 2017 License terms: CC-BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0)
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Figure 1: Patient selec-
tion criteria. AF: atrial 
 fibrillation; VTE: venous 
thromboembolism; OAC: 
oral anticoagulant.
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within one year of treatment initiation. This decrease in risk was 
driven by a reduction in all types of major bleeding, including GI 
(HR: 0.62, 95 % CI: 0.55–0.71, p<0.001), ICH (HR: 0.64, 95 % CI: 
0.50–0.80, p<0.001), and other major bleeding (HR: 0.57, 95 % CI: 
0.50–0.65, p<0.001) (▶ Figure 3).
Subgroup analyses
No significant interaction was found between the treatment and 
initial apixaban dose in regards to stroke/SE (p=0.848) and major 
bleeding (p=0.561). In the reduced and standard dose subgroups, 
apixaban was associated with a 34 % (HR: 0.66, 95 % CI: 0.51–0.85) 
and 32 % (HR: 0.68, 95 % CI: 0.58–0.78) lower risk of stroke/SE, re-
spectively, when compared to warfarin. Reduced and standard 
dose apixaban patients were associated with a 43 % (HR: 0.57, 95 % 
CI: 0.47–0.69) and 39 % (HR: 0.61, 95 % CI: 0.55–0.67) lower risk 
of major bleeding, respectively, when compared to corresponding 
warfarin patients (▶ Figure 4).
The results on stroke/SE and major bleeding were consistent 
across the three age groups. Compared to warfarin, apixaban was 
associated with a 27 % (HR: 0.73, 95 % CI: 0.54–0.98), 20 % (HR: 
0.80, 95 % CI: 0.62–1.03), and 38 % (HR: 0.62, 95 % CI: 0.52–0.73) 
lower risk of stroke/SE among patients aged <65, 65–74, and ≥75 
years, respectively. Among patients aged <65, 65–74, and ≥75 
years, apixaban treatment was associated with a 48 % (HR: 0.52, 
95 % CI: 0.42–0.65), 43 % (HR: 0.57, 95 % CI: 0.48–0.69), and 35 % 
(HR: 0.65, 95 % CI: 0.57–0.73) lower risk of major bleeding, re-
spectively, when compared to warfarin. No significant interaction 
on the stroke/SE (p=0.226) and major bleeding (p=0.181) out-
comes was found between treatment and age (▶ Figure 4).
Among patients with CHA2DS2-VASc scores <2, 2–3, and ≥4, 
apixaban treatment was associated with a 16 % (HR: 0.84, 95 % CI: 
0.45–1.58), 39 % (HR: 0.61, 95 % CI: 0.47–0.80), and 31 % (HR: 
0.69, 95 % CI: 0.59–0.80) lower risk of stroke/SE, respectively, 
when compared to warfarin. Compared to warfarin, apixaban was 
associated with a 48 % (HR: 0.52, 95 % CI: 0.35–0.77), 49 % (HR: 
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Table 2: Number of 
 patients with event 
and incidence rates 
during one-year 
 follow-up period. Stroke/SE
Ischaemic Stroke
Haemorrhagic Stroke
SE
Major Bleeding
ICH
GI Bleeding
Other Bleeding
Event rates are shown per 100 person-years. SE: systemic embolism; ICH: intracranial haemorrhage; GI: gastrointestinal.
Warfarin Cohort
(N=38,470)
Patients with Event
609
515
82
38
1,303
183
630
582
Incidence Rate
3.47
2.93
0.46
0.21
7.47
1.03
3.58
3.31
Apixaban Cohort 
(N=38,470)
Patients with Event
394
332
55
17
753
111
379
320
Incidence Rate
2.34
1.97
0.33
0.10
4.49
0.66
2.25
1.90
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0.51, 95 % CI: 0.44–0.61), and 34 % (HR: 0.66, 95 % CI: 0.59–0.73) 
lower risk of major bleeding among patients with CHA2DS2-VASc 
scores <2, 2–3, and ≥4, respectively. There was no significant inter-
action for stroke/SE between treatment and CHA2DS2-VASc 
scores (p=0.587), but a significant interaction for major bleeding 
was found (p=0.041).
No significant interaction was found between treatment and 
HAS-BLED score in regards to stroke/SE (p=0.439) and major 
bleeding (p=0.995). Compared to warfarin, apixaban was associ-
ated with a 27 % (HR: 0.73, 95 % CI: 0.56–0.94) and 35 % (HR: 
0.65, 95 % CI: 0.56–0.75) lower risk of stroke/SE in the low and 
high major bleeding risk subgroups (HAS-BLED scores <3 and 
≥3). Apixaban patients with HAS-BLED scores <3 (HR: 0.59, 95 % 
CI: 0.50–0.70) and ≥3 (HR: 0.59, 95 % CI: 0.53–0.66) had a signifi-
cantly lower risk of major bleeding compared to warfarin.
The interaction between treatment and different datasets was 
tested, and no significant interaction was found (stroke/SE: 
p=0.796; major bleeding: p=0.199). The stroke/SE results within 
each dataset were consistent with the overall results, with apixaban 
associated with significantly lower risk of stroke/SE versus warfa-
rin: HR=0.65 (95 % CI: 0.52–0.82) in MarketScan, HR=0.70 (95 % 
CI: 0.50–0.98) in PharMetrics, HR=0.62 (95 % CI: 0.48–0.81) in 
Optum, and HR=0.73 (95 % CI: 0.59–0.91) in Humana. Major 
bleeding results within each dataset were also consistent with the 
overall results, with apixaban associated with significantly lower 
risk of major bleeding versus warfarin: HR=0.63 (95 % CI: 
0.54–0.74) in MarketScan, HR=0.47 (95 % CI: 0.37–0.60) in Phar-
Metrics, HR=0.61 (95 % CI: 0.49–0.74) in Optum, and HR=0.63 
(95 % CI: 0.54–0.74) in Humana (▶ Figure 4).
Sensitivity analysis
In order to utilise a longer follow-up period, we conducted a sensi-
tivity analysis using the entire follow-up period. The mean follow-
up period for warfarin patients was longer than that for apixaban 
patients (200 vs 179 days). Although most patients had a follow-up 
less than one year, the maximum follow-up for warfarin patients 
was 2.8 years and 2.6 years for apixaban patients. Over the entire 
follow-up, patients treated with apixaban had a significantly lower 
risk of stroke/SE (HR: 0.67; 95 % CI: 0.60–0.76, p<0.001) and 
major bleeding (HR: 0.61; 95 % CI: 0.56–0.66, p<0.001) compared 
to warfarin.
Discussion
This retrospective “real-world” study examined and compared the 
risk of stroke/SE and major bleeding among NVAF patients who 
newly initiated warfarin and apixaban treatment using pooled data 
from four large US national claims datasets. We show that after 
PSM, apixaban initiation was associated with significant risk re-
ductions in stroke/SE and major bleeding compared to warfarin 
initiation. These benefits were consistent across apixaban dose 
regimens, various high-risk patient subgroups, and database 
sources.
This is by far the largest “real-world” evaluation on effective-
ness and safety of apixaban, with a sample size (76,940) more than 
four times that of the apixaban registrational trial ARISTOTLE 
(9,120 apixaban patients and 9,081 warfarin patients) (9). The ef-
fectiveness and safety results observed in this “real-world” study 
were generally consistent with those of the ARISTOTLE trial, 
where apixaban was superior to warfarin in reducing the risk of 
stroke/SE (HR: 0.79; 95 % CI: 0.66–0.95, p<0.001) with fewer 
major bleeding events (HR: 0.69; 95 % CI: 0.60–0.80, p<0.001) (9). 
In the current study, the different types of stroke/SE – including is-
chaemic stroke, haemorrhagic stroke, and SE – were all signifi-
cantly lower for apixaban compared to warfarin treatment; in the 
ARISTOTLE trial, only haemorrhagic stroke events were signifi-
cantly lower for patients treated with apixaban, and ischaemic 
stroke and SE were numerically lower for apixaban patients. Simi-
larly, the different types of major bleeding in the current study – 
including ICH, GI bleeding, and other major bleeding – were sig-
nificantly lower for patients treated with apixaban than those 
treated with warfarin. The ARISTOTLE trial also reported a sig-
nificantly lower risk of ICH and major bleeding at other sites for 
apixaban compared to warfarin. However, patients on apixaban 
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treatment in ARISTOTLE had numerically lower – but not signifi-
cantly different – rates of GI bleeding compared to those treated 
with warfarin (9). 
In our study, subgroup analyses revealed no significant interac-
tion between treatment and apixaban dosage, age, HAS-BLED 
score, or datasets in regards to the stroke/SE and major bleeding 
outcomes. Consistent with the main analysis, each subgroup 
analysis showed results of lowered stroke/SE and major bleeding 
risk associated with apixaban versus warfarin treatment. The re-
sults of the dosage, age, and bleeding risk stratification score sub-
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group analyses were also similar to those in the ARISTOTLE trial, 
which did not find significant interaction effects across those sub-
groups either (9, 28, 29).
For the CHA2DS2-VASc subgroup analysis, no significant inter-
action was detected in the analysis of stroke/SE, but the interaction 
term was significant in the analysis of major bleeding. Across all 
CHA2DS2-VASc scores, apixaban patients had a significantly lower 
risk of stroke/SE and major bleeding compared to warfarin. In AR-
ISTOTLE trial subgroup analysis on CHA2DS2-VASc scores, a sig-
nificant interaction effect was not found for either stroke/SE or 
major bleeding (29).
The follow-up period was limited to one year in the current 
study, given that most patients (85 %) had a follow-up shorter than 
one year. Additionally, apixaban entered the market recently, and 
patients treated with apixaban tended to have a shorter follow-up 
than those treated with warfarin. Restricting follow-up to one year 
allowed the duration to be more balanced between the apixaban 
and warfarin cohorts. After restricting the follow-up to one year, 
the average follow-up time was approximately 5–5.5 months in 
both cohorts. A sensitivity analysis was completed using the entire 
follow-up period, and the results were consistent. Patients treated 
with apixaban had a significantly lower risk of stroke/SE (HR: 
0.67; 95 % CI: 0.60–0.76, p<0.001) and major bleeding (HR: 0.61; 
95 % CI: 0.56–0.66, p<0.001) compared to those treated with war-
farin.
The results from the current study are also consistent with 
other “real-world” observational studies evaluating ARISTOTLE 
primary endpoints (stroke/SE and major bleeding) with data from 
US clinical practice (30, 31). In a recent publication using adminis-
trative claims data from Optum Labs Data Warehouse, 7,695 api-
xaban and 7,695 warfarin patients were matched. The HR for api-
xaban use compared to warfarin use was 0.67 (95 % CI: 0.46–0.98) 
for stroke/SE and 0.45 (95 % CI: 0.34–0.59) for major bleeding 
(30). This publication also found that haemorrhagic stroke, ICH, 
and GI bleeding were significantly lower among apixaban patients 
compared to warfarin patients. However, this paper did not find a 
significant difference for ischaemic stroke (HR: 0.83, 95 % CI: 
0.53–1.29), which may have been due to the smaller sample size 
(30). Consistent with the current study, another study evaluating 
major bleeding risk using MarketScan Commercial and Medicare 
Supplemental data found that apixaban patients had a 47 % lower 
risk of major bleeding among all users and a 45 % lower risk of 
major bleeding among standard dose users when compared to 
warfarin patients (31). 
This study pooled four large claims datasets and evaluated the 
effectiveness and safety outcomes comparing apixaban and warfa-
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rin. By pooling the datasets, this study increased the statistical 
power to evaluate the differences in the entire population and 
among several subgroup populations. Furthermore, since four da-
tasets were pooled, the generalisability of these results to the US 
population is substantially greater than prior, single-source 
studies. Findings from this study may inform the discussion of 
risks of stroke and major bleeding in the shared decision making 
process between healthcare providers and individual AF patients 
in selecting appropriate antithrombotic therapy (5).
Limitations
Our study has several limitations. First, only associations could be 
concluded from this retrospective observational study. Although 
cohorts were matched through PSM, potential residual con-
founders – such as over-the-counter use of aspirin and dose 
change for the warfarin treatment – exist. Due to the nature of the 
data, no laboratory results – such as creatinine clearance or INR – 
were available; time in therapeutic range information, which 
measures the quality of anticoagulation control among warfarin 
patients, was also unavailable. Second, given the nature of claims 
data, diagnoses were identified through ICD-9-CM codes and 
drug prescriptions were identified through prescription claims. 
Missing values, coding errors, and lack of clinical accuracy may 
have introduced bias into the study. Third, deaths that occurred 
outside the hospital setting are not captured; therefore, we were 
not able to accurately assess mortality. Death was obtained from 
hospital discharge records and reasons for mortality are not avail-
able, which may have biased the time-to-event analysis. Fourth, al-
though some of the datasets contain information from different 
insurance plans that do not overlap at the plan level, others are 
employer-based claims datasets which may contain duplicate pa-
tient records when pooled together; however, the number of such 
duplicates is likely to be small – based on a published estimate of 
0.5 % – and therefore unlikely to have any important effect on re-
sults (21). Fifth, only apixaban and warfarin were included in this 
analysis, and comparisons between the use of warfarin and other 
NOACs will be conducted in future analyses. The apixaban and 
warfarin comparison was conducted first because few studies have 
examined the safety and effectiveness of apixaban due to its recent 
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market entry. Prior studies evaluating the effectiveness of apixaban 
may have had limited statistical power (30); however, one of the 
main strengths of this study is the large sample size and sufficient 
statistical power necessary to evaluate both effectiveness and 
safety. Sixth, this study only included treatment-naïve apixaban 
and warfarin patients because a comparison between patients who 
switched from warfarin to apixaban and patients who continued 
on warfarin could be potentially confounded (the reason for a 
switch could be poor quality of INR control, which cannot be 
measured in the data source). Last, the mean follow-up time in our 
study was only 5–5.5 months. As more data becomes available, we 
plan to conduct further analyses using a longer follow-up period.
Furthermore, several factors may contribute to some of the dif-
ferences between this “real-world” study and clinical trials (32). 
First, the stroke/SE and major bleeding events in this “real-world” 
study were based on claims data; in the ARISTOTLE trial, these 
events were adjudicated. In contrast to the clinical trial, this “real-
world” study applied less-strict selection criteria and included a 
larger patient sample size. Additionally, warfarin management in 
the “real-world” may not be as good as that in the clinical trial, 
which may lead to higher rates of ischaemic stroke and GI bleed-
ing for patients treated with warfarin.
In conclusion, this “real-world” retrospective study offers the 
largest sample of comparisons between apixaban and warfarin pa-
tients to date. After PSM adjustment for differences in patient 
characteristics, NVAF patients treated with apixaban had a signifi-
cantly lower risk of stroke/SE and major bleeding compared to pa-
tients treated with warfarin. Importantly, these benefits were con-
What is known about this topic?
• Apixaban is the only non-VKA oral anticoagulant to show risk re-
duction in both stroke/systemic embolism (SE) and major bleed-
ing compared to warfarin in its Phase 3 trial.
• Due to apixaban’s recent market entry, prior “real-world” studies 
were limited by sample size and follow-up duration.
What does this paper add?
• Apixaban initiation is associated with a significantly lower risk of 
stroke/SE and major bleeding compared to warfarin initiation.
• Subgroup analyses (apixaban dosage, age strata, CHA2DS2-VASc 
or HAS-BLED score strata, or dataset source) all show consistently 
lower risks of stroke/SE and major bleeding associated with api-
xaban as compared to warfarin treatment.
© Schattauer 2017 License terms: CC-BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0)
© Schattauer 2017 Thrombosis and Haemostasis 6/2017
1082Li et al. Apixaban versus warfarin in non-valvular atrial fibrillation
License terms: CC-BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0) © Schattauer 
sistent across apixaban dose regimens, various high-risk patient 
subgroups, and database sources, providing complementary “real-
world” data to the clinical trial results.
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